Followers | 177 |
Posts | 24460 |
Boards Moderated | 11 |
Alias Born | 04/03/2002 |
Tuesday, January 11, 2022 10:35:24 AM
SciSparc Exploring Psychedelics as Possible Avenue to Expand Its IP Portfolio
TEL AVIV, Israel, Jan. 11, 2022 /PRNewswire/ -- SciSparc Ltd. (NASDAQ: SPRC), a specialty, clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system (the "Company"), announced that it has begun to examine the possibility of including psychedelic compounds as potential drug candidates for its intellectual property portfolio.
Despite being heavily regulated around the world, psychedelics have become an increasingly popular area for research. A report by Market Digits estimates that the sector could be worth more than $10 billion by 2027 as compared to $4.75 billion in 2020.
Adi Zuloff-Shani, PhD, Chief Technologies Officer of SciSparc, stated, "We have been tracking the research in psychedelics and are encouraged by the reports which appear to be favorable, particularly for disorders of the central nervous system. I expect our approach has the potential to be compatible with psychedelic compounds, so it behooves us to include them in the pool of candidates we consider when evaluating new opportunities."
"The industry is still in its infancy, but if we are to believe the analysts, psychedelic-centric therapies represent a significant market opportunity and another reason it is in our interest to establish SciSparc as a leader in the sector," Zuloff-Shani concluded.
About SciSparc (NASDAQ:SPRC):
SciSparc Ltd. is a specialty clinical-stage pharmaceutical company led by an experienced team of senior executives and scientists. Our focus is on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. With this focus, the Company is currently engaged in the following drug development programs based on THC and/or non-psychoactive cannabidiol (CBD): SCI-110 for the treatment of Tourette syndrome, for the treatment of obstructive sleep apnea and Alzheimer's disease and agitation; SCI-160 for the treatment of pain; and SCI-210 for the treatment of autism spectrum disorder and epilepsy.
Forward-Looking Statements:
This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. For example, SciSparc is using forward-looking statements when it discusses the potential inclusion of psychedelic compounds as potential candidates for its intellectual property portfolio and compatibility with SciSparc's approach, the future market opportunity for psychedelics and the potential favorability of psychedelics in addressing disorders of the central nervous system. Historic results of scientific research and clinical and preclinical trials do not guarantee that the conclusions of future research or trials will suggest identical or even similar conclusions. Because such statements deal with future events and are based on SciSparc's current expectations, they are subject to various risks and uncertainties and actual results, performance or achievements of SciSparc could differ materially from those described in or implied by the statements in this press release. The forward-looking statements contained or implied in this press release are subject to other risks and uncertainties, including those discussed under the heading "Risk Factors" in SciSparc's Annual Report on Form 20-F filed with the SEC on March 30, 2021, and in subsequent filings with the U.S. Securities and Exchange Commission. Except as otherwise required by law, SciSparc disclaims any intention or obligation to update or revise any forward-looking statements, which speak only as of the date they were made, whether as a result of new information, future events or circumstances or otherwise.
Investor Contact:
IR@scisparc.com
Tel: +972-3-616705
Recent SPRC News
- SciSparc to Acquire AutoMax • GlobeNewswire Inc. • 04/11/2024 12:15:00 PM
- SciSparc: MitoCareX Unveils Groundbreaking Discovery of Small Molecule Structure in Anti-Cancer Research • GlobeNewswire Inc. • 03/21/2024 12:58:00 PM
- SciSparc Granted Another Patent, Strengthening its Core Technology in Canada • GlobeNewswire Inc. • 03/18/2024 11:29:00 AM
- SciSparc Achieves Major Milestone with First Patient Dosed in Autism Spectrum Disorder Clinical Trial • GlobeNewswire Inc. • 03/14/2024 12:49:00 PM
- SciSparc: MitoCareX Reveals Promising Results with Discovery of Novel Anti-Cancer Small Molecule Structure • GlobeNewswire Inc. • 03/12/2024 12:14:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 03/08/2024 02:00:02 PM
- SciSparc Announces Enrollment of First Patient for its Clinical Trial for Children with Autism Spectrum Disorder • GlobeNewswire Inc. • 03/08/2024 12:11:00 PM
- SciSparc Granted Patent for Core Technology in Multiple Jurisdictions in Europe • GlobeNewswire Inc. • 03/07/2024 12:49:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 03/07/2024 05:15:11 AM
- SciSparc Issued Canadian Patent for Opioids Reduction Use in Pain Management Technology • GlobeNewswire Inc. • 03/06/2024 09:41:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 02/29/2024 02:07:12 PM
- SciSparc Delivers Treatment for Autism Spectrum Disorder Clinical Trial Enabling Commencement of Dosing • GlobeNewswire Inc. • 02/29/2024 01:35:00 PM
- Form F-1 - Registration statement for certain foreign private issuers • Edgar (US Regulatory) • 02/27/2024 09:15:05 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 02/27/2024 01:35:07 PM
- SciSparc-Clearmind Partnership Yields Three New International Patent Applications for MDMA, Ibogaine and Ketamine Compounds • GlobeNewswire Inc. • 02/27/2024 12:58:00 PM
- Clearmind Medicine Submits Three Additional International Patent Applications for Innovative MDMA, Ibogaine and Ketamine Compounds • GlobeNewswire Inc. • 02/27/2024 12:58:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 02/20/2024 09:27:17 PM
- Clearmind Medicine Submits Three International Patent Applications for Next Generation Classic Psychedelic-Based Compounds • GlobeNewswire Inc. • 02/20/2024 12:14:00 PM
- SciSparc and Clearmind Continue to Strengthen International Patent Portfolio with Next Generation Classic Psychedelic-Based Compounds • GlobeNewswire Inc. • 02/20/2024 12:14:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 02/12/2024 09:27:31 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 01/29/2024 09:00:11 PM
- SciSparc Announces Initiation of Patient Recruitment for its Clinical Trial with SCI-210 in Children with Autism Spectrum Disorder • GlobeNewswire Inc. • 01/29/2024 12:18:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 01/25/2024 02:05:42 PM
- SciSparc Ltd. Announces $20 Million Standby Equity Purchase Agreement • GlobeNewswire Inc. • 01/24/2024 12:42:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 01/22/2024 11:02:08 AM
Avant Technologies Equipping AI-Managed Data Center with High Performance Computing Systems • AVAI • May 10, 2024 8:00 AM
VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM
Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • ELEM • May 8, 2024 9:05 AM
Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM
Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM